{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:15:34Z","timestamp":1791486934043,"version":"4.3.4"},"reference-count":31,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Hypophosphatemia, osteomalacia, and fractures are complications of certain intravenous iron formulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study investigated risk factors for incident, severe, and persistent hypophosphatemia, and associated alterations in bone and mineral biomarkers following intravenous iron treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed data from the PHOSPHARE-IDA randomized clinical trials, comprising 245 patients aged 18 years or older with iron deficiency anemia at 30 outpatient clinics in the United States who received intravenous ferric carboxymaltose (FCM) or ferric derisomaltose (FDI). Outcome measures included serum phosphate, intact fibroblast growth factor-23 (iFGF23), 1,25-dihydroxyvitamin D (1,25(OH)2D), ionized calcium, parathyroid hormone (PTH), and alkaline phosphatase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>FCM was the only consistent risk factor for incident hypophosphatemia (&amp;lt; 2.0 mg\/dL; odds ratio vs FDI: 38.37; 95% CI: 16.62, 88.56; P &amp;lt; 0.001). Only FCM-treated patients developed severe hypophosphatemia (&amp;lt; 1.0 mg\/dL; 11.3%; 13\/115) or persistent hypophosphatemia (&amp;lt; 2.0 mg\/dL at study end; 40.0%; 46\/115). More severe hypophosphatemia associated with significantly greater increases in iFGF23, PTH, and alkaline phosphatase, and more severe decreases in 1,25(OH)2D and ionized calcium (all P &amp;lt; 0.05). Patients with persistent vs resolved hypophosphatemia demonstrated significantly greater changes in iFGF23, PTH, 1,25(OH)2D, and N-terminal procollagen-1 peptide levels (all P &amp;lt; 0.01), but alkaline phosphatase increased similarly in both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treatment with FCM was the only consistent risk factor for hypophosphatemia. Patients who developed severe or persistent hypophosphatemia after FCM treatment manifested more severe derangements in bone and mineral metabolism. Changes in bone biomarkers continued beyond resolution of hypophosphatemia, suggesting ongoing effects on bone that may help explain the association of FCM with osteomalacia and fractures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgab852","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T01:54:10Z","timestamp":1638323650000},"page":"1009-1019","source":"Crossref","is-referenced-by-count":51,"title":["Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose"],"prefix":"10.1210","volume":"107","author":[{"given":"Benedikt","family":"Schaefer","sequence":"first","affiliation":[{"name":"Christian Doppler Laboratory of Iron and Phosphate Biology at the Department of Medicine I, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Zoller","sequence":"additional","affiliation":[{"name":"Christian Doppler Laboratory of Iron and Phosphate Biology at the Department of Medicine I, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1127-1442","authenticated-orcid":false,"given":"Myles","family":"Wolf","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"issue":"19","key":"2022032516103947200_CIT0001","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJMra1401038","article-title":"Iron-deficiency anemia","volume":"372","author":"Camaschella","year":"2015","journal-title":"N Engl J Med."},{"issue":"10270","key":"2022032516103947200_CIT0002","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(20)32594-0","article-title":"Iron deficiency","volume":"397","author":"Pasricha","year":"2021","journal-title":"Lancet."},{"issue":"2","key":"2022032516103947200_CIT0003","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/trf.12289","article-title":"A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia","volume":"54","author":"Onken","year":"2014","journal-title":"Transfusion."},{"issue":"9","key":"2022032516103947200_CIT0004","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/00365521.2018.1498914","article-title":"Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice","volume":"53","author":"Stein","year":"2018","journal-title":"Scand J Gastroenterol."},{"issue":"7","key":"2022032516103947200_CIT0005","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/14740338.2021.1912010","article-title":"Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety","volume":"20","author":"Blumenstein","year":"2021","journal-title":"Expert Opin Drug Saf."},{"issue":"1","key":"2022032516103947200_CIT0006","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfaa011","article-title":"Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial","volume":"36","author":"Bhandari","year":"2021","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"2022032516103947200_CIT0007","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/17474086.2019.1575202","article-title":"A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment","volume":"12","author":"Pollock","year":"2019","journal-title":"Expert Rev Hematol."},{"issue":"9","key":"2022032516103947200_CIT0008","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/ajh.25564","article-title":"A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial","volume":"94","author":"Auerbach","year":"2019","journal-title":"Am J Hematol."},{"issue":"3","key":"2022032516103947200_CIT0009","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ajh.24633","article-title":"A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia","volume":"92","author":"Derman","year":"2017","journal-title":"Am J Hematol."},{"issue":"4","key":"2022032516103947200_CIT0010","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/ndt\/gft251","article-title":"Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial","volume":"29","author":"Onken","year":"2014","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"2022032516103947200_CIT0011","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/bcp.14643","article-title":"Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis","volume":"87","author":"Schaefer","year":"2020","journal-title":"Br J Clin Pharmacol."},{"issue":"5","key":"2022032516103947200_CIT0012","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA."},{"issue":"4","key":"2022032516103947200_CIT0013","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/apt.15386","article-title":"Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside","volume":"50","author":"Detlie","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"issue":"8","key":"2022032516103947200_CIT0014","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2022032516103947200_CIT0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","article-title":"FGF23 at the crossroads of phosphate, iron economy and erythropoiesis","volume":"16","author":"Edmonston","year":"2020","journal-title":"Nat Rev Nephrol."},{"key":"2022032516103947200_CIT0016","doi-asserted-by":"crossref","first-page":"100862","DOI":"10.1016\/j.mam.2020.100862","article-title":"Intravenous iron supplementation therapy","volume":"75","author":"Schaefer","year":"2020","journal-title":"Mol Aspects Med."},{"key":"2022032516103947200_CIT0017","volume-title":"Prescribing Information.","year":"2020"},{"key":"2022032516103947200_CIT0018","volume-title":"Prescribing Information.","year":"2020"},{"issue":"23","key":"2022032516103947200_CIT0019","doi-asserted-by":"crossref","first-page":"e124486","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight."},{"issue":"8","key":"2022032516103947200_CIT0020","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"Chotiyarnwong","year":"2020","journal-title":"Nat Rev Endocrinol."},{"issue":"6","key":"2022032516103947200_CIT0021","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/jcp.35.6.625","article-title":"Value of plasma calcium, phosphate, and alkaline phosphatase measurements in the diagnosis of histological osteomalacia","volume":"35","author":"Peach","year":"1982","journal-title":"J Clin Pathol."},{"key":"2022032516103947200_CIT0022","doi-asserted-by":"crossref","first-page":"116202","DOI":"10.1016\/j.bone.2021.116202","article-title":"Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management","volume":"154","author":"Schaefer","year":"2021","journal-title":"Bone."},{"key":"2022032516103947200_CIT0023","doi-asserted-by":"crossref","first-page":"bcr2017222851","DOI":"10.1136\/bcr-2017-222851","article-title":"Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration","volume":"2018","author":"Klein","year":"2018","journal-title":"BMJ Case Rep."},{"key":"2022032516103947200_CIT0024","volume-title":"Summary of Product Characteristics.","year":"2020"},{"key":"2022032516103947200_CIT0025","volume-title":"Prescribing Information (Brazil).","year":"2020"},{"key":"2022032516103947200_CIT0026","doi-asserted-by":"crossref","first-page":"115559","DOI":"10.1016\/j.bone.2020.115559","article-title":"Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency","volume":"141","author":"Frazier","year":"2020","journal-title":"Bone."},{"issue":"12","key":"2022032516103947200_CIT0027","doi-asserted-by":"crossref","first-page":"e0167146","DOI":"10.1371\/journal.pone.0167146","article-title":"Choice of high-dose intravenous iron preparation determines hypophosphatemia risk","volume":"11","author":"Schaefer","year":"2016","journal-title":"PLoS One."},{"issue":"11","key":"2022032516103947200_CIT0028","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.3390\/jcm9113587","article-title":"A pooled analysis of serum phosphate measurements and potential hypophosphataemia events in 45 interventional trials with ferric carboxymaltose","volume":"9","author":"Rosano","year":"2020","journal-title":"J Clin Med."},{"issue":"4","key":"2022032516103947200_CIT0029","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia: an emerging complication","volume":"26","author":"Zoller","year":"2017","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"6","key":"2022032516103947200_CIT0030","first-page":"391","article-title":"Symptomatic hypophosphataemic osteomalacia secondary to the treatment with iron carboxymaltose detected in bone scintigraphy","volume":"35","author":"Sangr\u00f3s Sah\u00fan","year":"2016","journal-title":"Rev Esp Med Nucl Imagen Mol."},{"issue":"6","key":"2022032516103947200_CIT0031","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1053\/j.gastro.2016.09.050","article-title":"Blood and bone loser","volume":"152","author":"Schaefer","year":"2017","journal-title":"Gastroenterology."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab852\/41724673\/dgab852.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/4\/1009\/42994510\/dgab852.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/4\/1009\/42994510\/dgab852.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T07:11:42Z","timestamp":1699859502000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/4\/1009\/6440289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,11,25]]},"published-print":{"date-parts":[[2022,3,24]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab852","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2021,11,25]]}}}